UNIGE document Scientific Article
previous document  unige:89077  next document
add to browser collection

Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens

Smith, Nicholas L
Wiggins, Kerri L
Harrington, Laura B
van Hylckama Vlieg, Astrid
Floyd, James S
Hwang, Melody
Bis, Joshua C
show hidden authors show all authors [1 - 14]
Published in JAMA Internal Medicine. 2014, vol. 174, no. 1, p. 25-31
Abstract IMPORTANCE: Little is known about the comparative cardiovascular safety of oral hormone therapy products, which impedes women from making informed safety decisions about hormone therapy to treat menopausal symptoms. OBJECTIVE: To compare the relative clinical cardiovascular safety of 2 commonly used oral estrogen drugs-conjugated equine estrogens (CEEs) and estradiol. DESIGN, SETTING, AND PARTICIPANTS: Population-based, case-control study from January 1, 2003, to December 31, 2009, comparing cardiovascular event risk associated with current CEEs and estradiol use in a large health maintenance organization in which the preferred formulary estrogen changed from CEEs to estradiol during the course of data collection. Participants were 384 postmenopausal women aged 30 to 79 years using oral hormone therapy. MAIN OUTCOMES AND MEASURES: Incident venous thrombosis was the primary clinical outcome, and incident myocardial infarction and ischemic stroke were secondary outcomes. As validation, an intermediate clotting phenotype, the endogenous thrombin potential-based normalized activated protein C sensitivity ratio, was measured in plasma of controls. RESULTS: We studied 68 venous thrombosis, 67 myocardial infarction, and 48 ischemic stroke cases, with 201 matched controls; all participants were current users of oral CEEs or estradiol. In adjusted analyses, current oral CEEs use compared with current oral estradiol use was associated with an increased venous thrombosis risk (odds ratio, 2.08; 95% CI, 1.02-4.27; P = .045) and an increased myocardial infarction risk that did not reach statistical significance (odds ratio, 1.87; 95% CI, 0.91-3.84; P = .09) and was not associated with ischemic stroke risk (odds ratio, 1.13; 95% CI, 0.55-2.31; P = .74). Among 140 controls, CEEs users compared with estradiol users had higher endogenous thrombin potential-based normalized activated protein C sensitivity ratios (P < .001), indicating a stronger clotting propensity. CONCLUSIONS AND RELEVANCE: In an observational study of oral hormone therapy users, CEEs use was associated with a higher risk of incident venous thrombosis and possibly myocardial infarction than estradiol use. This risk differential was supported by biologic data. These findings need replication and suggest that various oral estrogen drugs may be associated with different levels of cardiovascular risk.
Keywords AdultAgedCardiovascular DiseasesCase-Control StudiesEstradiol/therapeutic useEstrogen Replacement Therapy/methodsEstrogens/adverse effects/therapeutic useEstrogens, Conjugated (USP)/therapeutic useFemaleHumansMiddle AgedMyocardial Infarction/epidemiologyOdds RatioRisk FactorsStroke/epidemiologyVenous Thrombosis/epidemiology
PMID: 24081194
Full text
Article (Published version) (146 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group La maladie thromboembolique veineuse (808)
(ISO format)
SMITH, Nicholas L et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. In: JAMA Internal Medicine, 2014, vol. 174, n° 1, p. 25-31. doi: 10.1001/jamainternmed.2013.11074 https://archive-ouverte.unige.ch/unige:89077

224 hits

0 download


Deposited on : 2016-11-18

Export document
Format :
Citation style :